GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
Businesswire·2026-03-27 06:30
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025 GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025 Share Note: See paragraph on Estimated Full-Year 2025 Consolidated Financial Results at the end of this Press Release PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neu ...